Immunovaccine is a clinical-stage vaccine development company focused on advancing its patented DepoVax™ vaccine adjuvanting platform and product candidates for cancer therapy, infectious disease and animal health.
DepoVax is a well-developed technology platform which has demonstrated the ability to generate fast, strong and long-lasting immune responses against a range of targets. The technology serves as the foundation for the company’s broad vaccine product pipeline which includes two clinical-stage cancer vaccines – DPX-0907 and DPX-Survivac – that are being advanced internally at Immunovaccine. In a successfully completed Phase I study, DPX-0907 was demonstrated to be safe and capable of generating tumor-specific immune responses. Interim data from an ongoing Phase I trial has demonstrated similar results for DPX-Survivac.
Immunovaccine’s pipeline also includes a broad range of infectious diseases programs including vaccines in such indications as malaria, respiratory syncytial virus (RSV) and anthrax. In addition to the company's human health vaccine strategy, it continues to capture value from animal health vaccine applications.
Partnerships represent an essential element of Immunovaccine's business strategy and the company's collaborators include many leaders in their respective areas of focus including the National Institutes of Health, Weill Cornell Medical College and Zoetis (formerly Pfizer Animal Health).
This impressive collection of assets positions Immunovaccine with an advantageous growth strategy that leverages the unique attributes of DepoVax through the development of high-value internal vaccine candidates balanced with the upside of collaborative program advancement.
For Immunovaccine's latest Corporate presentation, please click here.
For Immunovaccine's latest Fact Sheet, please click here.